drugset / Trial / NCT01889433
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic hepatitis C.
Timeline
- Start
- 2013-07-10
- Primary completion
- 2015-12-02
- Completion
- 2015-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEPEGINTERFERON ALFA-2B | Unknown | 1.5 ug/kg | Subcutaneous |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |